Image assembly error corrected in formononetin mastitis paper
A correction in Frontiers in Immunology has revised a figure from the 2022 study on formononetin and lipopolysaccharide-induced mastitis. The update centers on Figure 6C, where the representative FITC-labeled albumin fluorescence image was misassigned during figure preparation because of a technical error in image assembly. The journal has now replaced the published figure with the corrected version and updated the original article record.
The correction does not introduce a new experiment or a new biological claim. It repairs the visual evidence attached to an already published mechanistic study, which matters because figure panels often carry the weight of the narrative in preclinical immunology. In this case, the panel in question was tied to the paper’s discussion of blood-milk barrier integrity, a central readout in mastitis biology.
What Figure 6 was intended to show
Figure 6 in the original work depicted suppression of LPS-induced disruption of the blood-milk barrier after administration of formononetin. The control group showed normal mammary gland tissue structure. The LPS group showed severe FITC-albumin infiltration and exfoliation of epithelial cells. In the treated groups receiving formononetin at 10, 20, or 30 mg/kg, the barrier gradually appeared more intact after treatment.
Blue spots represented nuclei, and green spots represented albumin. The visual readout is biologically important because albumin leakage into mammary tissue signals loss of barrier function, a classic feature of inflammatory damage in mastitis. When epithelial junctions fail, permeability rises, inflammatory mediators gain access to tissue compartments, and tissue injury can deepen quickly. A corrected fluorescence image therefore restores the integrity of the visual evidence supporting that barrier-focused conclusion.
The image correction sits alongside the paper’s broader mechanistic framework, which linked formononetin’s effects to suppression of inflammation and enhancement of barrier integrity through AhR-induced Src inactivation. The correction does not alter that mechanistic title or the article’s stated direction of effect. It simply replaces an incorrect representative image with the correct one.
Why the corrected panel matters for mastitis biology
Mastitis research depends heavily on histologic and fluorescence-based readouts because the disease is defined by tissue injury, inflammatory infiltration, and compromised epithelial barriers. FITC-albumin imaging is not decorative; it is a proxy for permeability. If albumin seeps through a damaged barrier, the tissue has already crossed a biologically meaningful threshold.
In that context, a misassigned image can distort how readers judge the degree of protection in a treatment arm. The corrected panel restores the visual continuity between the experimental design and the reported outcome. It also preserves the usefulness of the paper for investigators studying how natural compounds may dampen inflammatory signaling while stabilizing epithelial architecture.
One corrected image can change the evidentiary texture of an experiment even when the conclusion remains unchanged.
The published record has been updated
The journal states that the original version has been updated. This matters in the way corrections always matter in experimental medicine: the published archive should match the underlying data as closely as possible, especially when image-based endpoints are used to support mechanistic claims. The corrected version now stands as the authoritative record for the paper’s Figure 6.
The article remains open access under the Creative Commons Attribution License, and the correction preserves the citation trail for the 2022 study by Xiang, Shen, Gao, Liu, Hu, Liu, and Fu. The correction also lists the same clinical veterinary and laboratory affiliations, including Jilin University and Eastern Liaoning University, with correspondence directed to Bin Liu and Yunhe Fu.
Because this is a correction rather than a new experiment, there are no new sample sizes, no revised treatment arms, and no added endpoint analyses to interpret. The value of the notice lies in the cleanup of the visual record. In translational immunology, that cleanup is not cosmetic; it is part of the evidentiary chain that supports reproducibility.
Editorial significance for preclinical immunology
Corrections like this often pass quietly, yet they carry disproportionate importance in mechanistic work. A representative image anchors the reader’s confidence in the surrounding quantification, especially when the paper argues for changes in permeability, epithelial integrity, and inflammatory injury. Once a panel is known to have been misassigned, the corrected image becomes essential for anyone revisiting the study’s conclusions or comparing it with other mastitis models.
The underlying biology remains straightforward and clinically intuitive. LPS exposure drives inflammatory injury in mammary tissue, barrier breakdown follows, and albumin leakage marks that damage in fluorescence images. A treatment that appears to reverse those features must be judged on the accuracy of the figure set that displays them. The corrected Figure 6 therefore strengthens the clarity of the published record without expanding the paper’s scope.
The update also serves as a reminder that strong mechanistic claims depend on exact visual documentation. In studies built around tissue architecture, fluorescent tracers, and barrier phenotypes, the image is not supplementary fluff; it is part of the data. When that image is repaired, the publication becomes easier to trust on its own terms.
No new limitation is introduced by the correction beyond the fact that the original panel was misassigned. What remains fixed is the scope of the notice itself: a single figure replacement, a restored image sequence, and an updated article record tied to the 2022 formononetin mastitis paper.